Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ventricular Septal Defect Clear all
Recruiting Not applicable Interventional

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

NCT02744677
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Interventions
SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 12:46 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics

NCT01915277
View directory record Official record
Conditions
Transposition of the Great Arteries, Tetralogy of Fallot, Ventricular Septal Defect
Interventions
Dexmedetomidine
Drug
Lead sponsor
Carelon Research
Other
Eligibility
Up to 180 Days
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 21, 2026, 12:46 PM EDT
Not listed Phase 1Phase 2 Interventional

Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

NCT03079401
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome, Atrioventricular Canal
Interventions
MPC; rexlemestrocel-L
Biological
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 5 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 21, 2026, 12:46 PM EDT
Not yet recruiting Not applicable Interventional

Bypass Clear Priming VSD Cardiopulmonary Bypass Circuit Reduce Bypass Associated Inflammation?

NCT07393243
View directory record Official record
Conditions
Ventricular Septal Defect
Interventions
Clear priming of the bypass pump
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 12:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol

NCT01120964
View directory record Official record
Conditions
Atrial Septal Defect, Ventricular Septal Defect, Atrioventricular Septal Defect
Interventions
Intravenous L-Citrulline, Placebo of Intravenous L-Citrulline
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 6 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
St Louis, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 21, 2026, 12:46 PM EDT
Terminated Phase 3 Interventional

Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation

NCT00113698
View directory record Official record
Conditions
Heart Defects, Congenital, Heart Septal Defects, Ventricular, Heart Failure, Congestive
Interventions
Enalapril, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
Up to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 21, 2026, 12:46 PM EDT
Completed Not applicable Interventional Results available

Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study

NCT00647387
View directory record Official record
Conditions
Ventricular Septal Defects
Interventions
Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
48
States / cities
Phoenix, Arizona • Los Angeles, California • Madera, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 21, 2026, 12:46 PM EDT
Withdrawn Not applicable Interventional

Clinical Impact of Rapid Prototyping 3D Models for Surgical Management

NCT04788082
View directory record Official record
Conditions
Double Outlet Right Ventricle, Transposition of the Great Arteries, Truncus Arteriosus, Congenitally Corrected Transposition of the Great Arteries
Interventions
3D Printed Heart Model
Diagnostic Test
Lead sponsor
Children's National Research Institute
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 21, 2026, 12:46 PM EDT
Completed No phase listed Observational Results available

The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study

NCT03165526
View directory record Official record
Conditions
Post-Infarction Ventricular Septal Defect
Interventions
AMPLATZER™ Post-infarct Muscular VSD Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 21, 2026, 12:46 PM EDT
Recruiting Phase 1 Interventional

Beta-blocker Administration for Cardiomyocyte Division

NCT04713657
View directory record Official record
Conditions
Tetralogy of Fallot, Double Outlet Right Ventricle
Interventions
N-thymidine, Urine Collection, Echocardiogram, Cardiac MRI (CMR), Propranolol Hydrochloride, Placebo, Physical Exam, Specimen Collection
Other · Procedure · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Days to 60 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 21, 2026, 12:46 PM EDT
Terminated No phase listed Observational

Optimal Timing for Repair of Left to Right Shunt Lesions

NCT00229827
View directory record Official record
Conditions
Ventricular Septal Defects, Persistent Common Atrioventricular Canal
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 21, 2026, 12:46 PM EDT
Completed Not applicable Interventional

Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass

NCT01228305
View directory record Official record
Conditions
Congenital Heart Disease, Cardiopulmonary Bypass
Interventions
Acetaminophen
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Day to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 21, 2026, 12:46 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Energy Expenditure in Infants With Ventricular Septal Defects

NCT00006272
View directory record Official record
Conditions
Heart Septal Defects, Ventricular
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
3 Months to 4 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1994
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 12:46 PM EDT
Completed Phase 2 Interventional Results available

Measures to Lower the Stress Response in Pediatric Cardiac Surgery

NCT00848393
View directory record Official record
Conditions
Tetralogy of Fallot (TOF), Ventricular Septal Defects (VSD), Atrioventricular Septal Defects (AVSD)
Interventions
Fentanyl (High Dose), Fentanyl (Low Dose), Fentanyl (Low Dose) + Dexmedetomidine
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 3 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 21, 2026, 12:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Regional Anesthesia Following Pediatric Cardiac Surgery

NCT05688670
View directory record Official record
Conditions
Atrial Septal Defect, Ventricular Septal Defect, Pain, Procedural
Interventions
Regional Anesthesia, Wound infiltration, Ropivacaine 0.2% Injectable Solution
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
Up to 17 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 21, 2026, 12:46 PM EDT
Recruiting No phase listed Observational

Abbott Structural Heart Device Registry

NCT06590467
View directory record Official record
Conditions
Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions
Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 12:46 PM EDT
Completed Not applicable Interventional Results available

Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder

NCT00583791
View directory record Official record
Conditions
Heart Septal Defects, Ventricular
Interventions
Device closure with the AMPLATZER Muscular VSD Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
11
States / cities
Denver, Colorado • Orlando, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 21, 2026, 12:46 PM EDT
Terminated No phase listed Observational

Surgical Outcomes in Pediatric Patients With Coarctation and VSD

NCT00327795
View directory record Official record
Conditions
Diagnosis of Coarctation of the Aorta and VSD, Surgical Repair at CHOA, Between January 1, 2002 and December 31, 2005
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 21, 2026, 12:46 PM EDT
Completed Phase 1 Interventional

Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER

NCT00578708
View directory record Official record
Conditions
Membranous Ventricular Septal Defects
Interventions
AMPLATZER Membranous VSD Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
6
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 21, 2026, 12:46 PM EDT
Terminated Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

NCT05253209
View directory record Official record
Conditions
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions
L-citrulline, Plasmalyte A
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 12:46 PM EDT
Completed No phase listed Observational

Surgical Planning for Reconstruction of Complex Heart Defects

NCT00972608
View directory record Official record
Conditions
Double Outlet Right Ventricle
Interventions
Anatomic Reconstruction and Surgical Planning
Other
Lead sponsor
Emory University
Other
Eligibility
Up to 22 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 21, 2026, 12:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genes Causing Ebstein's Anomaly

NCT00497705
View directory record Official record
Conditions
Heart Septal Defects, Ventricle, Heart Defects, Congenital, Double Outlet Right Ventricle, Truncus Arteriosus, Persistent
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 12:46 PM EDT
Withdrawn Phase 1 Interventional

Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow

NCT01825369
View directory record Official record
Conditions
Heart Septal Defects, Ventricular, Atrioventricular Septal Defect
Interventions
IV L-carnitine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Months to 12 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 21, 2026, 12:46 PM EDT
Active, not recruiting Phase 2 Interventional

Optical Tissue Identification for Myocardial Architecture

NCT04017975
View directory record Official record
Conditions
Ventricular Septal Defect, Complete Atrioventricular Canal, Tetralogy of Fallot With Pulmonary Stenosis
Interventions
Fluorescite, Cellvizio 100 Series System with Confocal Miniprobes
Drug · Device
Lead sponsor
Aditya Kaza
Other
Eligibility
30 Days to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 21, 2026, 12:46 PM EDT